June 2026

Ninth JCA-AACR Special Joint Conference on Novel Therapies and Diagnostics in Upper Digestive and Head and Neck Cancers

TNX-1700, a First-in-Class CXCR4 Partial Agonist, Normalizes Myelopoiesis, and Enhances Anti-PD-1 Therapy in Gastric Cancer

June 2026

AANP 2026

Tonmya® (Cyclobenzaprine HCl Sublingual Tablets) Reduces Overall Impact of Fibromyalgia on Physical Symptoms and Functional Capacity

Tonmya® (TNX-102 SL; Cyclobenzaprine HCl Sublingual Tablets [CBP SL]) Improves Sleep Disturbance and Reduces Fatigue in Adults with Fibromyalgia

June 2026

EULAR 2026: Steady-state pharmacokinetic properties of a sublingual formulation of cyclobenzaprine (CBP) HCl: comparison to simulations of oral immediate-release CBP

May 2026

ISPOR 2026: Charactering Patients with Fibromyalgia: A U.S. Real-World Claims Analysis

May 2026

2nd Richard Slayman Clinical Xenotransplantation Workshop

TNX-1500: The History and Promise of α-CD154 Monoclonal Antibody Immunomodulation for Xenotransplantation

May 2026

Global Lyme Alliance Symposium

TNX-4800: A Long-Acting, Bactericidal, Human Monoclonal Antibody to Prevent Lyme Disease in the U.S.

May 2026

AAPA 2026

Treatment with TNX-102 SL (CBP SL) Produces Clinically Meaningful Improvements in Patient-Centered Outcomes in Fibromyalgia

Pharmacokinetic Characterization of Tonmya® (TNX-102 SL), a Sublingual Formulation of Cyclobenzaprine (CBP SL) for the Treatment of Adults with Fibromyalgia

Tonmya® (TNX-102 SL; CBP SL) Steady-State Pharmacokinetics Compared to Oral Simulations

April 2026

4th Annual Ticks and Tickborne Diseases Symposium: TNX-4800 Phase 1 Data and Plans for Adaptive Phase 2 Field Study

April 2026

American Association for Cancer Research (AACR) Annual Meeting 2026: In Vitro Characterization of Fully Human Antagonistic Anti-BTLA Monoclonal Antibodies

April 2026

American Association for Cancer Research (AACR) Annual Meeting 2026: Pharmacokinetics of TNX-1700 in Non-Human Primates and Human FcRn/Serum Albumin Transgenic Mice